The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., May. 30, 6:38 AM

Slide #17. Dynavax Technologies Corporation Secondary Offering

Company: Dynavax Technologies Corporation (NASDAQ:DVAX)
Date announced: 5/21/2020
Shares Offered: 14,000,000
Date of Pricing: 5/21/2020
Price Per Share: $5.00
Secondary Offering Details: Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common stock being offered in the public offering. All of the shares in the offering will be sold by Dynavax. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 5/21- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its previously announced underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, are expected to be approximately $70.0 million. In addition, Dynavax has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock. The offering is expected to close on or about May 27, 2020, subject to satisfaction of customary closing conditions.

Dynavax Technologies is a biopharmaceutical company focused on utilizing the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Co.'s commercial product, HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved for prevention of infection caused by various known subtypes of hepatitis B virus in adults age 18 years and older. Co.'s development efforts are focused on stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents. Co.'s pipeline of product candidates includes: SD-101, which is its cancer immunotherapy candidate; and DV281, which is an investigational TLR9 agonist.

DVAX SEC Filing Email Alerts Service

Open the DVAX Page at The Online Investor »

Company Name:  Dynavax Technologies Corp
Website:  www.dynavax.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding DVAX:  19
Total Market Value Held by ETFs:  $45.71M
Total Market Capitalization:  $455.00M
% of Market Cap. Held by ETFs:  10.05%
 

Open the DVAX Page at The Online Investor (in a new window) »

May 30, 2020    6:38 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
94th percentile
(ranked higher than approx. 94% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2020, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.